Skip to content
value.today

Harvard Bioscience, Inc.: financial analysis

Ratios worked out from 10 fiscal years of Harvard Bioscience, Inc.'s statements, compared with 53 companies in Medical Instruments.

Operating margin, 2025
-56.1%
Medical Instruments: 7.2%
Return on equity, 2025
-147.1%
Medical Instruments: 3.5%
Revenue growth, 3 years a year, 2025
-8.6%
Medical Instruments: 5.0%
Debt to equity, 2025
2.61×
Medical Instruments: 0.46×

Harvard Bioscience, Inc. scorecard#

Passes 6 of the 23 checks that could be worked out: strongest in valuation (3 of 6), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation3 of 6
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.7×Price to book 2.7× against Medical Instruments's median of 3.9×.
    • ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Medical Instruments's median of 3.0×.
    • ✓Free cash flow yield above 5%14.5%Free cash flow is 14.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • ✗The price assumes slower growth than the last three years'0.7%The price assumes 0.7% a year for ten years; revenue grew -8.6% a year over the last three.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-8.1%Revenue down 8.1% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-8.6%-8.6% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-8.6%-8.6% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✗Earnings per share grew in the newest year-1.28 vs -0.28Diluted EPS -1.28 in fiscal 2025 against -0.28 the year before (report's currency).
    • ✗Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against -$8 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-56.1%-56.1% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%-147.1%-147.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-56.1%-56.1% in fiscal 2025 against -6.1% in 2022.
  • Financial health2 of 5
    • ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.20 at the end of fiscal 2025.
    • ✗Debt below equity2.6×Debt to equity 2.61 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-37.4×Operating income -37.4 times interest in fiscal 2025.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.94Z-score -3.94 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year2.0%Diluted shares up 2.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Revenue fell 8.1% against the year before.
  • Net loss of $57 million, the 11th loss-making year in a row.
  • Operating income covers the interest bill only -37.4 times.
  • Goodwill and intangibles ($17 million) exceed shareholders' equity ($14 million).

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

5of 9
  • Made a profitno
  • Operations brought in cashyes
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsno
  • Current ratio roseyes
  • No new shares issuedyes
  • Gross margin roseno
  • Asset turnover roseyes

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

-3.94Distress zone(below 1.81, where the formula's author found most of the failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets0.33× 1.20.39
Retained earnings to assets-2.68× 1.4-3.75
Operating income to assets-0.61× 3.3-2.00
Market value to liabilities0.57× 0.60.34
Revenue to assets1.08× 11.08

Profitability#

Harvard Bioscience, Inc.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin57.7%58.2%58.9%53.7%56.9%56.2%56%
Operating margin-56.1%-6.6%1.7%-6.1%1.7%7.2%11%
Net margin-65.5%-13.2%-3.1%-8.4%-0.2%3.8%7%
Return on equity-147.1%-18.2%-4.7%-12.2%-0.4%3.5%4%
Return on assets-54.9%-9.4%-2.4%-6.2%-0.2%1.3%14%

Growth#

Harvard Bioscience, Inc.: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth-8.1%-16.1%-1.0%-4.7%16.5%8.9%4%
Revenue growth, 3 years a year-8.6%-7.5%3.2%-0.8%-0.5%5.0%11%
Revenue growth, 5 years a year-3.3%-4.1%-1.5%7.9%2.6%8.9%8%

Financial strength#

Harvard Bioscience, Inc.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity2.61×0.58×0.51×0.65×0.58×0.46×0%
Net debt$27 M$33 M$33 M$42 M$41 M$169 M57%
Interest cover-37.37×-7.76×———2.44×0%
Current ratio2.20×0.82×1.85×2.20×2.43×2.99×30%
Equity share of assets17.2%50.0%53.2%49.7%51.4%57.0%6%

Cash#

Harvard Bioscience, Inc.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$5 M$-1 M$12 M$-0 M$0 M$25 M39%
Free cash flow margin6.3%-1.3%10.9%-0.4%0.1%6.3%50%
Capital spending share of revenue1.5%2.8%1.6%1.4%1.0%2.6%—

Shareholder returns#

Harvard Bioscience, Inc.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Change in share count2.0%2.6%2.4%2.7%4.4%0.9%33%

Efficiency#

Harvard Bioscience, Inc.: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover0.84×0.71×0.79×0.74×0.75×0.55×74%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Harvard Bioscience, Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 53 companies in Medical Instruments that Harvard Bioscience, Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Harvard Bioscience, Inc.